Drug Profile
MB 314 - Meridian Biopharmaceuticals
Alternative Names: Glyco-engineered Lewis Y - specific monoclonal antibody - Meridian Biopharmaceuticals; Glyco-modified optimised antibody; Lewis Y antigen-targeted cancer antibody; MB 314Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Meridian Biopharmaceuticals
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cell death stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 23 Feb 2023 MB 314 is still in preclinical development phase for Cancer in Austria (Meridian Biopharmaceuticals website, February 2023)
- 28 Jul 2019 No recent reports of development identified for preclinical development in Cancer in Austria (Parenteral)
- 05 Jun 2015 Preclinical trials in Cancer in Austria (Parenteral) (Meridian Biotech website, June 2015)